Stock exchanges & markets

Overview Watchlists

Sandoz Canada wins Health Canada approval for generic Ozempic semaglutide

18. Sep 2026

(AWP Alliance News) - Novartis AG unit Sandoz Canada secured Health Canada clearance to market (Pr) Sandoz Semaglutide, a generic version of Novo Nordisk's Ozempic, for weekly treatment of type 2 diabetes in adults. The authorization covers subcutaneous pens delivering 0.25 mg or 0.5 mg doses, also a separate pen delivering 1 mg.

Sandoz Canada is preparing for a future commercial launch, targeting lower-cost access as demand for semaglutide injectors rises in Canada.

https://www.publicnow.com/view/7026BDD28B457B81523224927F02FDE7E69E9FF4…

Disclaimer: This news brief was created using generative artificial intelligence. Novartis AG published the original content used to generate this news brief via CNW on September 18, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • Compare ETFs systematically

    ETF Compass

    Find the products that suit your investment goals.

    Try the ETF Compass

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now